Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Advertisement
Articles by Timothy Hughes, MD, MBBS, FRACP, FRCPA
Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.
Advertisement
Latest Updated Articles
Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CMLPublished: June 7th 2024 | Updated:
Dr Hughes on the Safety of Asciminib in Ph+ CP-CMLPublished: July 18th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5